{"id":"NCT01835548","sponsor":"Neos Therapeutics, Inc","briefTitle":"NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","officialTitle":"A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2014-07","completion":"2014-07","firstPosted":"2013-04-19","resultsPosted":"2018-01-17","lastUpdate":"2018-01-17"},"enrollment":87,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"interventions":[{"type":"DRUG","name":"NT0102","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NT0102","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory classroom study.","primaryOutcome":{"measure":"Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Score","timeFrame":"Visit 8 (Day 42)","effectByArm":[{"arm":"Placebo","deltaMin":24.3,"sd":9.47},{"arm":"NT0102","deltaMin":17.3,"sd":7.48}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":["34081560","27183299"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":["Decreased appetite","Abdominal pain upper","Headache","Upper respiratory tract infection","Insomnia"]}}